Prabotulinumtoxin A - Daewoong Pharmaceuticals

Drug Profile

Prabotulinumtoxin A - Daewoong Pharmaceuticals

Alternative Names: DWP-450; Evosyal; Nabota; Prabotulinumtoxin A

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer ALPHAEON Corporation; Daewoong Pharmaceutical
  • Class Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glabellar lines
  • Phase III Muscle spasticity
  • Phase II/III Blepharospasm; Facial-wrinkles

Most Recent Events

  • 02 Aug 2018 Evolus resubmits BLA for Prabotulinumtoxin A for Glabellar lines in USA
  • 16 May 2018 Daewoong Pharmaceutical plans to launch prabotulinumtoxin A for Glabellar lines in USA by spring 2019
  • 16 May 2018 The US FDA issues an Establishment Inspection Report and a Complete Response Letter related to prabotulinumtoxin A's BLA in Glabellar lines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top